Genmab A/S Announces Results of Ofatumumab Phase II Study in Multiple Sclerosis

COPENHAGEN, Denmark, Sept. 10, 2010 (GLOBE NEWSWIRE) -- Summary: Genmab announces 48 week results from a Phase II study of ofatumumabin RRMS.

MORE ON THIS TOPIC